ResearcherMayo ClinicActive in the last 2 years

Verline Justilien

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6378-3469; OpenAlex author ID A5042862439; NIH RePORTER profile ID 10898550. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 1
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2026: 1 paper, 1 grant

Papers 1

Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-026-03860-3 ↗

Grants 1

ECT2 Isoform Switch in Pancreatic Cancer. R21CA296671 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nicole R Murray · 1 shared paper, 2026 · strength 0.28
- Paper Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-026-03860-3 ↗
Dania S. Al-Qasrawi · 1 shared paper, 2026 · strength 0.28
- Paper Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-026-03860-3 ↗
Alicia K. Fleming Martinez · 1 shared paper, 2026 · strength 0.28
- Paper Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-026-03860-3 ↗
Peter Störz · 1 shared paper, 2026 · strength 0.28
- Paper Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-026-03860-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.